Goldman Sachs downgraded Indian equities for the first time since March 2014 amid elevated valuations.
The January contract sank the most yesterday since March to its lowest in more than six weeks, a Bloomberg report said.
The company’s aim is to ensure that no commercial opportunity is wasted due to issues related to its manufacturing plants.
The acquisition, which includes dermatology and oral solid businesses of Sandoz in the U.S., has been done in an all-cash basis.
Fears that a possible resumption of full output at the world’s largest alumina refinery will lower prices hit the stock.
While PDUFA date for Xelpros would be November 2018, that for Elepsia XR is likely to be January 2019.
The cut in staples has benefited utilities and energy sector stocks which have seen an increased weightage.
The ongoing phase of growth adjustments has led to a broad-based consolidation across industries in India, DB Research said.
The move towards specialty is due to severe pressure in the U.S. market.
The company’s board at its meeting on Sept. 1 approved a capex plan of Rs 1,700 crore.
Shares of Apollo Hospitals Enterprise Ltd. gained over 25 percent in August, their best monthly performance since May 2009.
Goldman Sachs initiates coverage on Vedanta with a ‘Buy’ rating.
From software services providers to metal makers, how a weaker rupee will impact Indian companies...
The transaction was done in an Indian company through an unlisted entity instead of Colgate-Palmolive India.
Will L&T achieve its target of 18 percent return in equity by 2020-21? Here’s what the brokerages think.
CLSA’s analysis of both the leading parties’ manifestos suggests a consensus exists on several main policies.
Here are the top picks from Motilal Oswal based on Q1 earnings.
The combined EPS of the Nifty constituents missed the consensus by 7 percent in the quarter ended June.
Credit Suisse has downgraded the stock to ‘Underperform’ from ‘Neutral’ and revised the target price to Rs 715 from Rs 770.
Focus on domestic market helped Torrent Pharma improve its margins.
Key highlights from Teva’s financial results.